Company intelligence / Profile preview

Devyser

Stockholm/Hägersten, Swedendevyser.com ↗

Ownership: Private
Employees: ~121
Development stage: Commercial

Overview

Devyser’s diagnostic kits are CE-IVD marked and used globally in over forty-five countries. The company has achieved IVDR Class D approval for its non-invasive fetal RHD product. It continues to expand regulatory approvals internationally—including China Class III approval—and seeks FDA clearance for its NGS kidney transplant monitoring test. Its products are widely adopted by clinical laboratories due to their speed, accuracy, ease of use, and ability to streamline complex genetic workflows.

Therapeutic areas: PulmonologyOncologyHematologyCardiovascularWomen's Health
Modalities: Device (diagnostic kits)Software (for data analysis and interpretation)Molecular diagnostics technology (including amplicon-based NGS panels)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Devyser.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Devyser.

Explore the full profile